12 December 2025
EMA/CVMP/EWP/230324/2025
Committee for Veterinary Medicinal Products (CVMP)

Work plan for the Committee for Veterinary Medicinal Products (CVMP) Efficacy Working Party (EWP-V) 2026

Chairperson	**Status**
Chair: C. Muñoz Madero	Adopted by CVMP in December 2025

The activities outlined in the work plan for 2026 have been agreed considering the respective business priorities and may be subject to further review and reprioritisation in accordance with the business plan of the Agency.

1. Meetings scheduled for 2026

Plenary meetings:	3 (per meeting: Chair plus 12 members) 17-18 February 2026 (1.5 days) – virtual meeting 26-27 May 2026 (1.5 days) – virtual meeting 13-14 October 2026 (1.5 days) – physical meeting
Other meetings:	
Drafting / Expert groups	8-10 meetings (virtual; approximately 10 participants)
Workshop / Focus group	None
Trainings	- Guideline on data requirements for VMPs for zootechnical purposes (Q1 2026) - Guideline for the demonstration of efficacy for VMPs containing anticoccidial substances (Q1 2026) - Guideline for the evaluation of efficacy of ectoparasiticides - general requirements (Q4 2026)

If feasible and depending on the circumstances, some of the plenary meetings could be replaced by virtual meetings. Drafting / Expert group meetings are mainly regarded as complementary to plenary meetings.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

2. Product related issues

The following table provides the expected number per year of contributions (number of involvements in dossier) for scientific advice and product assessment, including pre- and post-authorisation issues.

Expected contribution in Scientific Advice	Expected contribution in Product Assessment
2	2

3. CVMP guidance documents

3.1. Guidance documents to be finalised after the consultation period

3.1.1. Guideline for the evaluation of efficacy of ectoparasiticides - general requirements (EMA/CVMP/EWP/507106/2023)

Action: Revised guideline to be finalised following public consultation.
Priority 2. Start date: ongoing, Completion date: Q3 2026.

Comments: Responsible group: EWP-V. Concept paper published in July 2023.

3.1.2. Guideline on the conduct of bioequivalence studies for veterinary medicinal products (EMA/CVMP/016/2000)

Action: Revised guideline (rev. 5) to be finalised following public consultation.
Priority 1. Start date: Q1 2025, Completion date: Q4 2026.

Comments: Responsible groups: EWP-V, QWP. Concept paper published in July 2024.

3.1.3. Guideline on veterinary medicinal products controlling *Varroa destructor* parasitosis in bees (EMA/CVMP/EWP/459883/2008)

Action: Revised guideline (rev. 2) to be finalised following public consultation.
Priority 2. Start date: Q1 2025, Completion date: Q4 2026.

Comments: Responsible group: EWP-V. Concept paper published in July 2024.

3.1.4. Guideline on dossier requirements for anticancer medicinal products for dogs and cats (EMA/CVMP/28510/2008)

Action: Revised guideline (rev. 2) to be finalised following public consultation.
Priority 3. Start date: Q1 2025, Completion date: Q4 2026.

Comments: Responsible groups: EWP-V, QWP, SWP-V. Concept paper published in July 2024.

3.2. Guidance documents to be released for consultation

3.2.1. Guideline on using owner assessment as efficacy parameter

Action: Concept paper to be published. New guideline to be developed.
Priority 2. Start date: Q1 2026, Completion date: Q4 2027.

Comments: Responsible group: EWP-V.

3.3. New topics/concept papers to be prepared

3.3.1. Revision of the guideline on pharmaceutical fixed combination products (EMA/CVMP/83804/2005)

Action: Develop a concept paper for the revision of the guideline. Revise the guideline accordingly.
Priority 2. Start date: Q1 2026, Completion date: Q4 2027.
Comments: Responsible group: EWP-V.

3.3.2. Revision of the guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances (EMA/CVMP/383441/2005)

Action: Develop a concept paper for the revision of the guideline. Revise the guideline accordingly.
Priority 1. Start date: Q1 2026, Completion date: Q2 2027.
Comments: Responsible groups: AWP, EWP-V.

3.3.3. Promote prudent and responsible use of antiparasitics in the EU. Develop an infographic on lack of expected efficacy for antiparasitic veterinary medicinal products

Action: Infographic to be developed.
Priority 2. Start date: ongoing, Completion date: Q2 2026.
Comments: Responsible groups: EWP-V, PhVWP-V.

4. VICH guidelines and activities

4.1. VICH guideline on fixed combination products (pharmaceuticals)

Action: Contribute to EU position.
Priority 2. Start date: ongoing, Completion date: 2026.
Comments: VICH to elaborate a 'Status report' on the topic.
Responsible group: EWP-V.

4.2. VICH guideline on between strength biowaivers

Action: Contribute to EU position.
Priority 2. Start date: ongoing, Completion date: beyond 2026.
Comments: VICH to elaborate a new GL on between strength biowaivers.
Responsible groups: QWP, EWP-V.

5. EU regulatory activities

5.1. Collaboration with EFSA

Action:	Provide contribution to EFSA opinions in accordance with Art. 59 of Regulation (EC) No 726/2004 as amended, as required.
Comments:	None.

5.2. Assessor training

Action:	Provide advice/active participation for training of assessors, as required. Training topics for 2026 are indicated under section 1 of this document. Contribute to the development of the veterinary training curriculum. Review and update the veterinary efficacy sub-curriculum.
Comments:	EWP-V to reflect on needs for training for 2027.

5.3. Other

Action:	Provide contributions to guidelines and questions raised by other working parties and ad hoc expert groups, as required.
Comments:	None.

6. Activities with external parties

6.1. Meetings with interested parties

None foreseen.

6.2. Regulatory authorities outside the EU

As required.

7. Organisational matters

7.1. List of adopted organisational documents

Mandate, objectives, and rules of procedure for working parties under the quality, non-clinical, methodology, clinical and veterinary domains (EMA/299541/2025).

7.2. List of organisational documents to be developed/revised in the forthcoming 2 years

None foreseen.

*7.3. List of proposed scientific guidelines for the next work plan**

7.3.1. Guidance documents to be finalised after the consultation period

- Guideline on using owner assessment as efficacy parameter
- Revised guideline on pharmaceutical fixed combination products
- Revised guideline on the summary of product characteristics (SPC) for veterinary medicinal products containing antimicrobial substances

7.3.2. Guidance documents to be released for consultation

- None foreseen

*The actual items to be included in EWP-V work plan for 2027 will be considered and agreed by the CVMP.